Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., . . . Karp, J. E. (2018). Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leuk Res.
Chicago Stili AlıntıZeidner, Joshua F., et al. "Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7 + 3) in Newly Diagnosed High-risk Acute Myeloid Leukemia (AML)." Leuk Res 2018.
MLA AlıntıZeidner, Joshua F., et al. "Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7 + 3) in Newly Diagnosed High-risk Acute Myeloid Leukemia (AML)." Leuk Res 2018.